Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
Share Article
Allyx Therapeutics expects to advance ALX-001, an mGluR5 modulator for Alzheimer’s disease, into clinical trials in 2021 NEW HAVEN, Conn. (PRWEB) January 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx’s novel therapy for Alzheimer’s disease. The agreement includes a sublicense of certain rights from Yale University. To protect vulnerable neurons and preserve cognition in Alzheimer’s patients, Allyx expects to advance ALX-001, a small-molecule modulator of metabotropic glutamate receptor 5 (mGluR5), licensed from Bristol Myers Squibb, into clinical trials in 2021.